Fruquintinib: Completed Phase III enrollment

Chi-Med completed enrollment of 416 patients in the double-blind, placebo-controlled, Chinese Phase III FRESCO

Read the full 145 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE